A phase 3 trial of Edge Therapeutics’ treatment for aneurysmal subarachnoid hemorrhage has come to a halt after an interim analysis. The data committee found Edge’s nimodipine microparticles were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results